Protara Therapeutics to Share Updates on TARA-002 Trial
NEW YORK — Protara Therapeutics, Inc. (Nasdaq: TARA), a firm dedicated to innovative treatments for cancer and rare diseases, has announced plans for an important conference call and live webcast. This event is set for 8:30 a.m. ET, aimed at presenting the most recent safety and efficacy data from the ongoing Phase 2 ADVANCED-2 trial of TARA-002, targeting non-muscle invasive bladder cancer (NMIBC).
This trial has drawn significant attention, particularly as it includes evaluations from participants who have reached the critical 12-month mark, demonstrating the progress in research related to disease management. A segment of this data will also be showcased in an interactive poster session at the upcoming American Urological Association Annual Meeting, further underscoring the importance of these findings in the medical community.
Joining the Conference Call
Those interested in accessing the live call can do so by registering beforehand, which will provide relevant dial-in details. The event will not only cover data details but also allow for participant interaction, fostering an engaging atmosphere. The webcast will be preserved for future viewing, ensuring stakeholders can revisit the updates shared during this significant occasion.
Insight into ADVANCED-2 Trial
The ADVANCED-2 trial (NCT05951179) represents a Phase 2 open-label study evaluating the effects of intravesical TARA-002 on NMIBC patients presenting with carcinoma in situ or CIS. This patient group is critically important, particularly those who are Bacillus Calmette-Guérin (BCG)-unresponsive, as they represent a subset of individuals needing innovative therapies. The trial is structured smartly to align with the U.S. Food and Drug Administration's guidelines for treatment options.
TARA-002 and its Unique Developmental Background
TARA-002 is an experimental cell therapy in development specifically for NMIBC, which has shown promise for patients with lymphatic malformations as well. This therapy has obtained a Rare Pediatric Disease Designation from the FDA, highlighting its significance and potential to address unmet medical needs.
Interestingly, TARA-002 is derived from a master cell bank of a specific Streptococcus pyogenes, paralleling the immunopotentiator OK-432, which is already utilized effectively in Japan. Protara Therapeutics has successfully demonstrated that TARA-002 maintains comparable manufacturing quality, which is critical as the company progresses further in its research and application of this investigational therapy.
The Mechanism Behind TARA-002 Treatment
The mechanism through which TARA-002 operates is particularly fascinating. When administered, it is believed to activate both innate and adaptive immune cells situated within the tumor environment. This immune activation is crucial as it enhances pro-inflammatory responses, linked to cytokines such as tumor necrosis factor (TNF)-alpha and various interleukins. Such activities not only contribute to the direct killing of tumor cells but also stimulate immunogenic pathways that enhance the overall antitumor immune reactivity, a promising prospect for patients suffering from NMIBC.
Understanding Non-Muscle Invasive Bladder Cancer (NMIBC)
Bladder cancer ranks as the sixth most widespread cancer in the country, with NON-MIBC accounting for a substantial majority—approximately 80% of all diagnoses. Each year, over 65,000 new NMIBC cases emerge, making it a significant health concern. NMIBC specifically refers to cancer located within the lining of the bladder, without invasive growth into the muscle layers. Effective management and innovative treatments are essential for improving outcomes for these patients.
About Protara Therapeutics, Inc.
Protara Therapeutics stands at the forefront of biopharmaceutical innovation, focusing on developing breakthrough therapies for cancer and rare diseases. The firm continues to advance its lead candidate, TARA-002, while simultaneously exploring other critical areas such as IV Choline Chloride, aimed at addressing patients' nutritional needs during parenteral nutrition.
Exciting developments continue as the company assesses TARA-002 in its Phase 2 trials targeting those affected by NMIBC. This includes substantial research efforts directed towards achieving meaningful clinical results in both adult and pediatric patient populations.
Company Contact Information
For further inquiries, please reach out to:
Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
Frequently Asked Questions
What is the significance of the ADVANCED-2 trial?
The ADVANCED-2 trial is crucial for assessing the safety and efficacy of TARA-002 in NMIBC patients, presenting significant data to guide future treatments.
How can I join the conference call?
Interested individuals can register online to receive dial-in information for the conference call.
What is TARA-002?
TARA-002 is an investigational cell therapy targeting non-muscle invasive bladder cancer, demonstrating potential efficacy in early trials.
Why is NMIBC important to address?
With NMIBC representing roughly 80% of bladder cancer cases, effective management options are critical for patient outcomes and quality of life.
What is Protara’s main focus?
Protara Therapeutics focuses on pioneering treatments for cancer and rare diseases, with TARA-002 as its leading development candidate.
